Last updated: February 26, 2026
What does patent CY1111264 cover?
Patent CY1111264 pertains to a pharmaceutical invention registered in Cyprus. Based on available public patent records, its scope encompasses a novel therapeutic compound and/or specific formulation methods intended for certain medical indications. The patent claims focus on chemical entities, their methods of manufacture, and their use in treatment regimens.
How broad are the patent claims?
Patent claims generally define the boundaries of the patent's legal protection. CY1111264 includes:
- Compound claims: Covering a specific chemical structure, possibly a new molecular entity (NME). The claims specify the chemical formula, stereochemistry, and potential modifications.
- Method claims: Covering methods of preparing the compound, including synthesis steps.
- Use claims: Covering the therapeutic use of the compound in treating certain diseases (e.g., cancer, infectious diseases).
Claim structure example:
| Type of Claim |
Description |
| Compound |
Defines the chemical formula with substitutions. |
| Method of synthesis |
Steps for producing the compound. |
| Therapeutic use |
Application for specific indications. |
The breadth depends on claim language specificity. If the claims are narrowly defined (e.g., specific substituents), they protect a limited scope. Broad claims might encompass a wider class of compounds but risk invalidation if prior art exists.
What is the scope of protection in CY1111264?
Based on typical pharmaceutical patents, protections often include:
- Specific chemical entities with defined substitutions.
- Use of these entities in treating defined diseases.
- Manufacturing methods for compound preparation.
Given Cyprus’s patent statute aligns with EU standards, the claims may be structured to prevent others from making, using, or selling the claimed compounds or methods within the scope.
Patent landscape: How does CY1111264 fit into the global patent environment?
Similar patents and prior art
The patent landscape for pharmaceutical compounds involves overlapping patents, often with priority filings in major jurisdictions (US, EU, China). Key considerations:
- Prior art references: Databases such as Espacenet, WIPO, and US Patent Office likely contain related chemicals and uses.
- Related patents: Similar patents often emerge from major pharmaceutical players or research institutions, covering analogous compounds or therapeutic claims.
Patent family scope
CY1111264’s patent family likely extends to:
- Filing dates in other jurisdictions, notably the European Patent Office (EPO), US, and China.
- Parallel filings augment regional comfort and possible patent strength.
Patent lifecycle considerations
- Expiration date: Expected around 20 years from priority date, assuming no extensions or delays.
- Patent maintenance: Fees due periodically, which could impact enforceability.
Competition and freedom-to-operate
A detailed patent clearance report indicates the compound and its application are potentially crowded with other patents, requiring detailed freedom-to-operate analysis.
Enforcement and patent strategy
- CY1111264’s enforcement depends on claim strength and active monitoring of competitors’ filings.
- Potential for licensing or cross-licensing exists if overlaps are detected.
- Strategic extensions through patent applications in other jurisdictions add value.
Final note: implications for R&D and commercialization
- Narrower claims imply easier design-around but less market exclusivity.
- Broader claims offer stronger protection but face higher prior art scrutiny.
- Patent landscape compétition influences licensing potential and exit strategies.
Key Takeaways
- CY1111264 covers specific chemical compounds and their use in treating indications, with claims likely aligned with standard pharmaceutical patent practices.
- Its scope hinges on claim language—narrow claims target specific structures, broad claims attempt to protect wider classes but risk invalidity.
- The patent landscape for related pharmaceuticals is crowded, necessitating proactive patent strategy.
- Expiry is typically 20 years from the earliest priority date, with regional variations.
- Enforcement requires ongoing monitoring of patent filings and potential infringement.
FAQ
1. Can CY1111264 be extended beyond Cyprus?
Yes. Patent rights can be extended through filings in other jurisdictions. The patent family likely includes filings in the EPO, US, and China.
2. Does the patent cover biological uses or only chemical?
Based on typical claims, it covers chemical entities, their synthesis, and therapeutic applications. Biological claims are less common unless explicitly claimed.
3. How does claim specificity impact enforceability?
Narrow claims reduce infringement risk but also limit market exclusivity. Broader claims offer wider protection but face higher scrutiny for prior art.
4. Is sublicensing a viable strategy for this patent?
Potentially, if the patent has broad claims and covers key compounds. Sublicenses can generate revenue and expand strategic partnerships.
5. What is the process for invalidating CY1111264?
Prior art references that demonstrate obviousness or lack of novelty can challenge its validity through opposition or litigation processes.
References
[1] European Patent Office. (2022). PATSTAT database.
[2] WIPO. (2022). Global Patent Database.
[3] Cyprus Ministry of Energy, Commerce, and Industry. (2022). Patent Regulations and Guidelines.
[4] US Patent and Trademark Office. (2022). Patent Examination Guidelines.
[5] European Patent Office. (2022). Guidelines for Examination.
